Molecular Hydrogen as an Adjuvant Therapy in Comorbid Sjögren’s Syndrome, SLE, and ILD: A Case Report on Immune Modulation and Fatigue Reduction
Tsai YH, Lu JW, Tu JI, Li YJ, Hsu HF, Chang FH, Ho YJ, Lui SW, Hsieh TY, Wang KY, Liu FC. · In vivo (Athens, Greece). 2025;39(4):2228-2235.
Study at a glance
Human
Human participants studied for metabolic and lipid health. See eligibility criteria in the linked full text.
Full text reports an oral H₂-generating preparation. No numeric quantity is inferred beyond the source wording. · The full article describes the H₂ intervention but does not report a numeric H₂ concentration.
Multiple article-specific time points; see the linked full methods.
Article-reported result excerpt (24 words maximum): “Following hydrogen therapy, immunological changes were observed, including: a) Increased CD95+ T cells ([Figure 3]); b) Decreased TIM-3+ cytotoxic T cells (Tc) ([Figure 4]);…” This excerpt is not a complete result summary; consult the linked full text for all positive and null findings.
Human evidence; design, sample size and comparator limit interpretation. Funding or grant information is reported in the full article. The article declares no conflicts of interest.
What kind of evidence is this?
Human
Case report
Metabolic and lipid health
Other forms
Information not yet classified
Some editorial classification fields are still pending. The source-reported outcomes and result are shown below; Hydrogenology does not infer a positive or negative signal from prose automatically.
Methods
Human participants studied for metabolic and lipid health. See eligibility criteria in the linked full text.
Human study; the article does not state one consolidated sample total, so no total is inferred.
Multiple article-specific time points; see the linked full methods.
Full text reports an oral H₂-generating preparation. No numeric quantity is inferred beyond the source wording.
an oral H₂-generating preparation — H₂ only unless the full text explicitly reports oxygen co-delivery.
The full article describes the H₂ intervention but does not report a numeric H₂ concentration.
Control or comparison condition reported in the full article; see the linked methods for arm-specific details.
Outcomes and reported result
survival or mortality, clinical symptoms or functional scores, tumor growth or cancer markers, inflammation and cytokines, oxidative-stress and antioxidant markers, apoptosis or cell injury
Article-reported result excerpt (24 words maximum): “Following hydrogen therapy, immunological changes were observed, including: a) Increased CD95+ T cells ([Figure 3]); b) Decreased TIM-3+ cytotoxic T cells (Tc) ([Figure 4]);…” This excerpt is not a complete result summary; consult the linked full text for all positive and null findings.
The complete machine-readable article was checked for source identity, methods, intervention quantities, results, tables, funding and conflict declarations. This public record is based on the full article.
A reported association, difference or mechanism is not automatically a clinical benefit.
Limitations and applicability
Human evidence; design, sample size and comparator limit interpretation. Funding or grant information is reported in the full article. The article declares no conflicts of interest.
Applies only to the population and protocol reported in this metabolic and lipid health article.
No single-study GRADE certainty rating is assigned. Read how records and evidence assessments are prepared.
Sources and record status
PMID: 40579023 · DOI: 10.21873/invivo.14018
A free full article is available through PubMed Central.
Official PubMed/PMC full article; source identity, intervention data and declarations re-audited 25 August 2026.
25 August 2026
Help people check the facts before they buy.
Hydrogenology keeps 665 source-checked records accessible without advertising or product promotion.
Help us correct the recordReport a discrepancy
Send the exact difference between this page and the linked source. The study reference is attached automatically.